Clinical Trials Directory

Trials / Completed

CompletedNCT01694966

The Safety and Efficacy of Methylene Blue MMX® Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy

Status
Completed
Phase
Phase 3
Study type
Interventional
Enrollment
1,249 (actual)
Sponsor
Cosmo Technologies Ltd · Industry
Sex
All
Age
50 Years – 75 Years
Healthy volunteers
Accepted

Summary

Evaluation of the histologically proven adenoma and carcinoma detection rate in patients undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with 200 mg of Methylene Blue MMX® tablets.

Conditions

Interventions

TypeNameDescription
DRUGMethylene Blue MMX®
DRUGPlaceboSugar pill manufactured to mimic Methylene Blue MMX® tablet.

Timeline

Start date
2013-09-01
Primary completion
2016-10-01
Completion
2016-10-01
First posted
2012-09-27
Last updated
2017-11-06
Results posted
2017-11-06

Locations

19 sites across 8 countries: United States, Belgium, Canada, Germany, Italy, Lithuania, Netherlands, United Kingdom

Source: ClinicalTrials.gov record NCT01694966. Inclusion in this directory is not an endorsement.